Results 211 to 220 of about 130,905 (247)
SynchronoGeometry in Financial Economics: A Phase-Based Theory of Systemic Risk and Financial Crises
Saadat Samadi
openalex +1 more source
The Economics of Conflicts of Interest in Financial Institutions
, 2008 Deborah Kidd
openalex +1 more source
Biofuels, Bioproducts and Biorefining, EarlyView.Abstract The study identified process development priorities toward the feasible production of five value‐added biochemicals in a sugarcane biorefinery based on achievable bioconversion performances. Multiple process scenarios using A‐molasses as feedstock were simulated in Aspen Plus® via direct microbial conversions.
Manasseh K. Sikazwe +2 more
wiley +1 more source
Biofuels, Bioproducts and Biorefining, EarlyView.Abstract The premise of a bioeconomy is the replacement of nonrenewable and unsustainable fossil‐derived resources and associated technologies with more sustainable alternatives. The adoption of biobased chemicals contributes toward the growth of a bioeconomy and is dependent on market and industry requirements.
Prisha Mandree +2 more
wiley +1 more source
Social prescribing within five European countries: a protocol of a cross-country qualitative analysis. [PDF]
BMJ OpenTierney S +11 more
europepmc +1 more source
PARADOX OF CONSUMPTION IN ISLAMIC ECONOMICS: BETWEEN ANTI-ISRAF PRINCIPLE AND FINANCIAL POLICIES
Dewi Insyirahti Salsabilla +1 more
openalex +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source